Evogene (NASDAQ:EVGN) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a research report sent to investors on Wednesday. The brokerage issued a sell rating on the biotechnology company’s stock.

Evogene Price Performance

EVGN opened at $1.57 on Wednesday. The company has a 50 day simple moving average of $1.59 and a two-hundred day simple moving average of $2.62. The firm has a market cap of $8.43 million, a P/E ratio of -0.35 and a beta of 1.30. Evogene has a 1-year low of $1.20 and a 1-year high of $10.40.

Evogene (NASDAQ:EVGN) last issued its quarterly earnings results on Thursday, November 21st. The biotechnology company reported ($1.31) earnings per share (EPS) for the quarter. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC bought a new position in Evogene Ltd. (NASDAQ:EVGN) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.